COVID-19 Archives | Page 56 of 202 | Be Korea-savvy
Struggling Small Merchants Express Frustration over Meager Virus Curb Relaxation

Struggling Small Merchants Express Frustration over Meager Virus Curb Relaxation

SEOUL, March 18 (Korea Bizwire) — Restaurants, cafes and other small business owners on Friday expressed frustration over the government’s latest COVID-19 rule relaxation, with many questioning the efficacy of the gathering restriction when the nation is faced with its biggest virus wave to date. Earlier in the day, the government decided to raise the [...]

Child Obesity Spreads in Pandemic Era: Study

Child Obesity Spreads in Pandemic Era: Study

SEOUL, March 18 (Korea Bizwire) — The obesity rate among children and teenagers has increased following the spread of COVID-19, which has forced many to remain indoors. A research team from Nowon Eulji Medical Center compared the body mass index (BMI) data of children who visited the hospital before and during the pandemic. Of 113 [...]

Korean Scientists Identify Cause Behind COVID-19 Aftereffects Using Machine Learning

Korean Scientists Identify Cause Behind COVID-19 Aftereffects Using Machine Learning

GWANGJU, March 17 (Korea Bizwire) – The Gwangju Institute of Science and Technology (GIST) said Wednesday that its research team had identified the cause of COVID-19 aftereffects using machine learning, a type of artificial intelligence (AI) technology. Thus far, it has been reported that COVID-19 causes various aftereffects, including not only respiratory symptoms such as [...]

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

SHANGHAI, China, March 16 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the first patient was dosed in its Phase III trial of VV116 for the treatment of moderate to severe [...]

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

SYDNEY, Australia, March 15 (Korea Bizwire) –  ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of complications, has dosed its first participants in a Phase 2a flu-challenge study. The Phase 2a trial is a single centre, prospective, [...]